SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-3
Document Type: S-3
Date Filed: 2025-11-26
Accession Number: 0001213900-25-115554
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025115554/ea0266812-s3_synergy.htm

Chunk 11 of 26
Word Count: 1496
Character Count: 9508

Document Content:

directions received by the depositary from participants with respect to ownership of beneficial interests in the registered global security that had been held by the depositary. PLAN OF DISTRIBUTION Initial Offering and Sale of Securities Unless otherwise set forth in a prospectus supplement accompanying this prospectus, we may sell the securities being offered hereby, from time to time, by one or more of the following methods: ● to or through underwriting syndicates represented by managing underwriters; ● through one or more underwriters without a syndicate for them to offer and sell to the public; ● through “at the market” offerings; ● through block trades; ● through dealers or agents; and ● to investors directly in negotiated sales or in competitively bid transactions. Offerings of securities covered by this prospectus also may be made into an existing trading market for those securities in transactions at other than a fixed price, either:

●	on or through the facilities of the Nasdaq Capital Market or any other securities exchange or quotation or trading service on which those securities may be listed, quoted, or traded at the time of sale; and/or

●	to or through a market maker other than on the securities exchanges or quotation or trading services set forth above.

Those at-the-market offerings,
if any, will be conducted by underwriters acting as principal or agent of the Company, who may also be third-party sellers of securities
as described above. The prospectus supplement with respect to the offered securities will set forth the terms of the offering of the offered
securities, including:

●	the name or names of any underwriters, dealers or agents;

●	the purchase price of the offered securities and the proceeds to us from such sale;

●	any underwriting discounts and commissions or agency fees and other items constituting underwriters’ or agents’ compensation;

●	any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers;

●	any securities exchange on which such offered securities may be listed; and

●	any underwriter, agent or dealer involved in the offer and sale of any series of the securities.

The distribution of the securities
may be effected from time to time in one or more transactions:

●	at fixed prices, which may be changed;

●	at market prices prevailing at the time of the sale;

●	at varying prices determined at the time of sale; or

●	at negotiated prices.

Each prospectus supplement
will set forth the manner and terms of an offering of securities including:

●	whether that offering is being made to underwriters, through agents or directly to the public;

●	the rules and procedures for any auction or bidding process, if used;

●	the securities’ purchase price or initial public offering price; and

●	the proceeds we anticipate from the sale of the securities, if any.

In addition, we may enter
into derivative or hedging transactions with third parties, or sell securities not covered by this prospectus to third parties in privately
negotiated transactions. The applicable prospectus supplement may indicate, in connection with such a transaction, that the third parties
may sell securities covered by and pursuant to this prospectus and an applicable prospectus supplement. If so, the third party may use
securities pledged by us or borrowed from us or others to settle such sales and may use securities received from us to close out any related
short positions. We may also loan or pledge securities covered by this prospectus and an applicable prospectus supplement to third parties,
who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus
and the applicable prospectus supplement.

Sales Through Underwriters

If underwriters are used in
the sale of some or all of the securities covered by this prospectus, the underwriters will acquire the securities for their own account.
The underwriters may resell the securities, either directly to the public or to securities dealers, at various times in one or more transactions,
including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The obligations
of the underwriters to purchase the securities will be subject to certain conditions. Unless indicated otherwise in a prospectus supplement,
the underwriters will be obligated to purchase all the securities of the series offered if any of the securities are purchased.

Any initial public offering
price and any concessions allowed or reallowed to dealers may be changed intermittently.

Sales Through Agents

Unless otherwise indicated
in the applicable prospectus supplement, when securities are sold through an agent, the designated agent will agree, for the period of
its appointment as agent, to use specified efforts to sell the securities for our account and will receive commissions from us as will
be set forth in the applicable prospectus supplement.

Securities bought in accordance
with a redemption or repayment under their terms also may be offered and sold, if so indicated in the applicable prospectus supplement,
in connection with a remarketing by one or more firms acting as principals for their own accounts or as agents for us. Any remarketing
firm will be identified and the terms of its agreement, if any, with us and its compensation will be described in the prospectus supplement.
Remarketing firms may be deemed to be underwriters in connection with the securities remarketed by them.

If so indicated in the applicable
prospectus supplement, we may authorize agents, underwriters or dealers to solicit offers by certain specified institutions to purchase
securities at a price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery
on a future date specified in the prospectus supplement. These contracts will be subject only to those conditions set forth in the applicable
prospectus supplement, and the prospectus supplement will set forth the commissions payable for solicitation of these contracts.

Direct Sales

We may also sell offered securities
directly to institutional investors or others. In this case, no underwriters or agents would be involved. The terms of such sales will
be described in the applicable prospectus supplement.

General Information

Broker-dealers, agents or
underwriters may receive compensation in the form of discounts, concessions or commissions from us and/or the purchasers of securities
for whom such broker-dealers, agents or underwriters may act as agents or to whom they sell as principal, or both. This compensation to
a particular broker-dealer might be in excess of customary commissions.

Underwriters, dealers and
agents that participate in any distribution of the offered securities may be deemed “underwriters” within the meaning of the
Securities Act, so any discounts or commissions they receive in connection with the distribution may be deemed to be underwriting compensation.
Those underwriters and agents may be entitled, under their agreements with us, to indemnification by us against certain civil liabilities,
including liabilities under the Securities Act, or to contribution by us to payments that they may be required to make in respect of those
civil liabilities. Certain of those underwriters or agents may be customers of, engage in transactions with, or perform services for,
us or our affiliates in the ordinary course of business. We will identify any underwriters or agents, and describe their compensation,
in a prospectus supplement. Any institutional investors or others that purchase offered securities directly, and then resell the securities,
may be deemed to be underwriters, and any discounts or commissions received by them from us and any profit on the resale of the securities
by them may be deemed to be underwriting discounts and commissions under the Securities Act.

We will file a supplement
to this prospectus, if required, pursuant to Rule 424(b) under the Securities Act, if we enter into any material arrangement with a broker,
dealer, agent or underwriter for the sale of securities through a block trade, special offering, exchange distribution or secondary distribution
or a purchase by a broker or dealer. Such prospectus supplement will disclose:

●	the name of any participating broker, dealer, agent or underwriter;

●	the number and type of securities involved;

●	the price at which such securities were sold;

●	any securities exchanges on which such securities may be listed;

●	the commissions paid or discounts or concessions allowed to any such broker, dealer, agent or underwriter, where applicable; and

●	other facts material to the transaction

In order to facilitate the
offering of certain securities under this prospectus or an applicable prospectus supplement, certain persons participating in the offering
of those securities may engage in transactions that stabilize, maintain or otherwise affect the price of those securities during and after
the offering of those securities. Specifically, if the applicable prospectus supplement permits, the underwriters of those securities
may over-allot or otherwise create a short position in those securities for their own account by selling more of those securities than
have been sold to them by us and may elect to cover any such short position by purchasing those securities in the open market.